person · Reporting owner

Brennan Aoife

Disclosed activity across 5 companies

Tapewire entity: 34400
SEC CIK: 0001714563

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Climb Bio, Inc.CLYM · Entity 5064	Director · President and CEO	June 27, 2026	June 30, 2026
KYNTRA BIO, INC.FGEN · Entity 7431	Director	June 05, 2024	June 07, 2024
SYNLOGIC, INC.SYBX · Entity 7801	Director · President and CEO	November 10, 2023	November 15, 2023
Xilio Therapeutics, Inc.XLO · Entity 7122	Director	June 11, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Climb Bio, Inc.

Report date June 27, 2026 · Filed June 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	118,633	Reported balance After 2026-06-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-27 · Exercise / conversion · Acquired 68,750 · Balance 118,633 F1: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock F2: Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.
Common StockSEC Table I · non-derivative	Direct	87,731	Reported balance After 2026-06-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-06-29 · Sale · Disposed 30,902 · Balance 87,731 F3: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs. F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	137,500	Reported balance After 2026-06-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-27 · Exercise / conversion · Disposed 68,750 · Balance 137,500 F5: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock

F2: Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.

F3: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F5: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F6: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

KYNTRA BIO, INC.

Report date June 05, 2024 · Filed June 07, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2034-06-04	Direct	70,000	Reported balance After 2024-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-05 · Grant · Acquired 70,000 · Balance 70,000 F1: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.

SYNLOGIC, INC.

Report date November 10, 2023 · Filed November 15, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $202.95 · Expires 2027-05-15	Direct	0	Reported balance After 2023-11-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-11-10 · Disposition to issuer · Disposed 5,591 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.25 · Expires 2028-03-14	Direct	0	Reported balance After 2023-11-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-11-10 · Disposition to issuer · Disposed 3,733 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $143.25 · Expires 2028-06-05	Direct	0	Reported balance After 2023-11-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-11-10 · Disposition to issuer · Disposed 3,600 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $118.65 · Expires 2028-10-31	Direct	0	Reported balance After 2023-11-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-10 · Disposition to issuer · Disposed 9,999 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.85 · Expires 2029-03-05	Direct	0	Reported balance After 2023-11-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-10 · Disposition to issuer · Disposed 12,332 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.50 · Expires 2030-03-10	Direct	0	Reported balance After 2023-11-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-11-10 · Disposition to issuer · Disposed 12,352 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.50 · Expires 2031-03-10	Direct	0	Reported balance After 2023-11-10 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-11-10 · Disposition to issuer · Disposed 18,999 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2032-02-04	Direct	0	Reported balance After 2023-11-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-11-10 · Disposition to issuer · Disposed 28,943 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F5: The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.30 · Expires 2033-03-16	Direct	0	Reported balance After 2023-11-10 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-11-10 · Disposition to issuer · Disposed 42,999 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F6: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.30 · Expires 2033-03-16	Direct	0	Reported balance After 2023-11-10 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-11-10 · Disposition to issuer · Disposed 8,666 · Balance 0 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F7: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2027-05-15	Direct	5,591	Reported balance After 2023-11-10 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-11-10 · Grant · Acquired 5,591 · Balance 5,591 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2028-03-14	Direct	3,733	Reported balance After 2023-11-10 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-11-10 · Grant · Acquired 3,733 · Balance 3,733 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2028-06-05	Direct	3,600	Reported balance After 2023-11-10 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2023-11-10 · Grant · Acquired 3,600 · Balance 3,600 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2028-10-31	Direct	9,999	Reported balance After 2023-11-10 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2023-11-10 · Grant · Acquired 9,999 · Balance 9,999 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2029-03-05	Direct	12,332	Reported balance After 2023-11-10 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2023-11-10 · Grant · Acquired 12,332 · Balance 12,332 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2: The shares subject to this option are fully vested as of the date hereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2030-03-10	Direct	12,352	Reported balance After 2023-11-10 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2023-11-10 · Grant · Acquired 12,352 · Balance 12,352 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2031-03-10	Direct	18,999	Reported balance After 2023-11-10 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2023-11-10 · Grant · Acquired 18,999 · Balance 18,999 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2032-02-04	Direct	28,943	Reported balance After 2023-11-10 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2023-11-10 · Grant · Acquired 28,943 · Balance 28,943 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F5: The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2033-03-16	Direct	42,999	Reported balance After 2023-11-10 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2023-11-10 · Grant · Acquired 42,999 · Balance 42,999 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F6: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2033-03-16	Direct	8,666	Reported balance After 2023-11-10 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2023-11-10 · Grant · Acquired 8,666 · Balance 8,666 F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F7: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.

Filing footnotes · ownership attribution and instrument terms

F1: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F2: The shares subject to this option are fully vested as of the date hereof.

F3: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.

F4: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.

F5: The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.

F6: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.

F7: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.

Xilio Therapeutics, Inc.

Report date June 11, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2036-06-10	Direct	5,000	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Ra Pharmaceuticals, Inc.

Report date April 02, 2020 · Filed April 03, 2020

Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.88 · Expires 2029-06-11	Direct	0	Reported balance After 2020-04-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-04-02 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.36 · Expires 2028-09-21	Direct	0	Reported balance After 2020-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-04-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 29, 2026 Filed Jun 30, 2026 23:50 UTC	Climb Bio, Inc. CLYM · Entity 5064	SaleCommon Stock	30,902	$13.17	$406,979.34	Disclosure SEC source: 0001193125-26-291131 · ownership.xml · nonDerivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,731 F3 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
June 27, 2026 Filed Jun 30, 2026 23:50 UTC	Climb Bio, Inc. CLYM · Entity 5064	Exercise / conversionRestricted Stock Units · Derivative	68,750	$0.00	$0.00	Disclosure SEC source: 0001193125-26-291131 · ownership.xml · derivative · entry 3 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 68,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. F6 · derivative.expiration_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. Read SEC document
June 27, 2026 Filed Jun 30, 2026 23:50 UTC	Climb Bio, Inc. CLYM · Entity 5064	Exercise / conversionCommon Stock	68,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-291131 · ownership.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock F2 · balance_after: Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan. Read SEC document
June 11, 2026 Filed Jun 12, 2026 20:07 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $7.99	$0.00	Disclosure SEC source: 0001193125-26-269395 · ownership.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:05 UTC	Climb Bio, Inc. CLYM · Entity 5064	GrantStock Option (Right to Buy) · Derivative	700,000	$0.00 Strike: $3.81	$0.00	Disclosure SEC source: 0001193125-26-007670 · ownership.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2036-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. Read SEC document
June 30, 2025 Filed Jul 1, 2025 20:37 UTC	Climb Bio, Inc. CLYM · Entity 5064	SaleCommon Stock	20,618	$1.22	$25,153.96	Disclosure SEC source: 0000950170-25-092284 · ownership.xml · nonDerivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,132 F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.20 to $1.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:37 UTC	Climb Bio, Inc. CLYM · Entity 5064	Exercise / conversionRestricted Stock Units · Derivative	68,750	$0.00	$0.00	Disclosure SEC source: 0000950170-25-092284 · ownership.xml · derivative · entry 3 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,250 Underlying: Common Stock · 68,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. F5 · derivative.expiration_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:37 UTC	Climb Bio, Inc. CLYM · Entity 5064	Exercise / conversionCommon Stock	68,750	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-092284 · ownership.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock. Read SEC document
June 11, 2025 Filed Jun 12, 2025 20:37 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	GrantStock Option (right to buy) · Derivative	31,000	$0.00 Strike: $0.69	$0.00	Disclosure SEC source: 0001415889-25-016971 · form4-06122025_080611.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document
January 13, 2025 Filed Jan 15, 2025 21:15 UTC	Climb Bio, Inc. CLYM · Entity 5064	GrantStock Option (Right to Buy) · Derivative	1,150,000	$0.00 Strike: $1.92	$0.00	Disclosure SEC source: 0000950170-25-005840 · ownership.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,150,000 Underlying: Common Stock · 1,150,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: This option was granted on January 13, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service. Read SEC document
June 27, 2024 Filed Jun 27, 2024 23:05 UTC	Climb Bio, Inc. ELYM · Entity 5064	GrantRestricted Stock Units · Derivative	275,000	$0.00	$0.00	Disclosure SEC source: 0000950170-24-078688 · ownership.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. Read SEC document
June 27, 2024 Filed Jun 27, 2024 23:05 UTC	Climb Bio, Inc. ELYM · Entity 5064	GrantStock Option (Right to Buy) · Derivative	550,000	$0.00 Strike: $7.53	$0.00	Disclosure SEC source: 0000950170-24-078688 · ownership.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option was granted on June 27, 2024 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through June 27, 2028, subject to the Reporting Person's continued service. Read SEC document
June 13, 2024 Filed Jun 17, 2024 20:10 UTC	Xilio Therapeutics, Inc. XLO · Entity 7122	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0001415889-24-017154 · form4-06172024_080637.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option was granted on June 13, 2024 and will vest in three equal installments on June 13, 2025, June 13, 2026 and June 13, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document
June 05, 2024 Filed Jun 7, 2024 00:00 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $1.21	$0.00	Disclosure SEC source: 0001415889-24-015854 · form4-06062024_080605.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	8,666	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 20 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,666 Underlying: Common Stock · 8,666 shares Expires 2033-03-16 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F7 · derivative.exercise_date: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	42,999	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 19 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,999 Underlying: Common Stock · 42,999 shares Expires 2033-03-16 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F6 · derivative.exercise_date: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	28,943	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 18 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,943 Underlying: Common Stock · 28,943 shares Expires 2032-02-04 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F5 · derivative.exercise_date: The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	18,999	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 17 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,999 Underlying: Common Stock · 18,999 shares Expires 2031-03-10 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4 · derivative.exercise_date: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	12,352	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 16 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,352 Underlying: Common Stock · 12,352 shares Expires 2030-03-10 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3 · derivative.exercise_date: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	12,332	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 15 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,332 Underlying: Common Stock · 12,332 shares Expires 2029-03-05 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	9,999	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 14 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,999 Underlying: Common Stock · 9,999 shares Expires 2028-10-31 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	3,600	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 13 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires 2028-06-05 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	3,733	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 12 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,733 Underlying: Common Stock · 3,733 shares Expires 2028-03-14 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	5,591	Not disclosed Strike: $1.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 11 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,591 Underlying: Common Stock · 5,591 shares Expires 2027-05-15 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	8,666	Not disclosed Strike: $9.30	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 10 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,666 shares Expires 2033-03-16 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F7 · derivative.exercise_date: These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	42,999	Not disclosed Strike: $9.30	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 9 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,999 shares Expires 2033-03-16 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F6 · derivative.exercise_date: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	28,943	Not disclosed Strike: $29.25	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 8 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,943 shares Expires 2032-02-04 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F5 · derivative.exercise_date: The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	18,999	Not disclosed Strike: $52.50	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 7 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,999 shares Expires 2031-03-10 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F4 · derivative.exercise_date: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	12,352	Not disclosed Strike: $25.50	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 6 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,352 shares Expires 2030-03-10 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F3 · derivative.exercise_date: The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	12,332	Not disclosed Strike: $128.85	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 5 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,332 shares Expires 2029-03-05 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	9,999	Not disclosed Strike: $118.65	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 4 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,999 shares Expires 2028-10-31 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	3,600	Not disclosed Strike: $143.25	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 3 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires 2028-06-05 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	3,733	Not disclosed Strike: $149.25	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,733 shares Expires 2028-03-14 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
November 10, 2023 Filed Nov 15, 2023 00:23 UTC	SYNLOGIC, INC. SYBX · Entity 7801	Disposition to issuerStock Option (right to buy) · Derivative	5,591	Not disclosed Strike: $202.95	Not disclosed	Disclosure SEC source: 0000950170-23-063927 · ownership.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,591 shares Expires 2027-05-15 F1 · derivative.exercise_price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F1 · price: In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. F2 · derivative.exercise_date: The shares subject to this option are fully vested as of the date hereof. Read SEC document
June 09, 2023 Filed Jun 9, 2023 23:55 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	SaleCommon Stock	2,739	$17.52	$47,987.28	Disclosure SEC source: 0001209191-23-036080 · doc4.xml · nonDerivative · entry 3 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,947 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F4 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.26 to $17.72. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 09, 2023 Filed Jun 9, 2023 23:55 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	SaleCommon Stock	1,994	$16.74	$33,379.56	Disclosure SEC source: 0001209191-23-036080 · doc4.xml · nonDerivative · entry 2 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,686 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F3 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.17 to $17.14. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:55 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	12,666	$0.00 Strike: $17.13	$0.00	Disclosure SEC source: 0001209191-23-036080 · doc4.xml · derivative · entry 4 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,666 Underlying: Common Stock · 12,666 shares Expires 2033-06-06 F5 · derivative.exercise_date: Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 23:55 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	8,289	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036080 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,680 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
April 03, 2023 Filed Apr 5, 2023 20:15 UTC	SYNLOGIC, INC. SYBX · Entity 7801	SaleCommon Stock	19,042	$0.58	$10,964.38	Disclosure SEC source: 0000899243-23-010715 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,301 F1 · shares: Represents the number of shares sold by the reporting person on April 3, 2023 to cover the tax liability in connection with the vesting of three restricted stock awards, vesting on April 1, 2023, that were granted in 2020, 2021, and 2022. The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5750 to $0.5798, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:08 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	25,684	$0.00 Strike: $9.00	$0.00	Disclosure SEC source: 0001209191-22-038603 · doc4.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,684 Underlying: Common Stock · 25,684 shares Expires 2032-06-15 F2 · derivative.exercise_date: Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
June 16, 2022 Filed Jun 22, 2022 01:08 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	15,777	$0.00	$0.00	Disclosure SEC source: 0001209191-22-038603 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,391 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
April 04, 2022 Filed Apr 6, 2022 20:39 UTC	SYNLOGIC, INC. SYBX · Entity 7801	SaleCommon Stock	8,894	$2.45	$21,753.83	Disclosure SEC source: 0000899243-22-014110 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,343 F1 · shares: Represents the number of shares sold by the reporting person on April 4, 2022 to cover the tax liability in connection with the vesting of two restricted stock awards, vesting on April 1, 2022, that were granted in 2020 and 2021. The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 26, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.45, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document
February 04, 2022 Filed Feb 8, 2022 21:05 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	434,160	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0000899243-22-005213 · doc4.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,160 Underlying: Common Stock · 434,160 shares Expires 2032-02-04 F2 · derivative.exercise_date: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on the grant date, which is February 4, 2022, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date. Read SEC document
February 04, 2022 Filed Feb 8, 2022 21:05 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantCommon Stock	106,920	$0.00	$0.00	Disclosure SEC source: 0000899243-22-005213 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,237 F1 · shares: The shares of restricted stock were granted on February 4, 2022, and will vest beginning on April 1, 2022 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date. Read SEC document
May 26, 2021 Filed May 28, 2021 23:01 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	7,800	$0.00 Strike: $20.86	$0.00	Disclosure SEC source: 0001209191-21-036668 · doc4.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-05-25 F2 · derivative.exercise_date: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
May 26, 2021 Filed May 28, 2021 23:01 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantCommon Stock	4,700	$0.00	$0.00	Disclosure SEC source: 0001209191-21-036668 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,614 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document
March 10, 2021 Filed Mar 12, 2021 21:50 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantStock Option (right to buy) · Derivative	285,000	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0000899243-21-011334 · doc4.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Stock · 285,000 shares Expires 2031-03-10 F2 · derivative.exercise_date: The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on April 1, 2021, with the first installment vesting on May 1, 2021, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date. Read SEC document
March 10, 2021 Filed Mar 12, 2021 21:50 UTC	SYNLOGIC, INC. SYBX · Entity 7801	GrantCommon Stock	71,250	$0.00	$0.00	Disclosure SEC source: 0000899243-21-011334 · doc4.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,317 F1 · shares: The shares of restricted stock were granted on March 10, 2021, and will vest beginning on April 1, 2021 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date. Read SEC document
August 05, 2020 Filed Aug 7, 2020 23:45 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	10,400	$0.00 Strike: $42.65	$0.00	Disclosure SEC source: 0001209191-20-045766 · doc4.xml · derivative · entry 3 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 Underlying: Common Stock · 10,400 shares Expires 2030-08-05 F3 · derivative.exercise_date: Option vests quarterly over three years from August 5, 2020. Read SEC document
August 05, 2020 Filed Aug 7, 2020 23:45 UTC	KYNTRA BIO, INC. FGEN · Entity 7431	GrantStock Option (Right to Buy) · Derivative	6,496	$0.00 Strike: $42.65	$0.00	Disclosure SEC source: 0001209191-20-045766 · doc4.xml · derivative · entry 2 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,496 Underlying: Common Stock · 6,496 shares Expires 2030-08-05 F2 · derivative.exercise_date: Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.